"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approves pembrolizumab (Keytruda) for patients with recurrent locally advanced or metastatic MCC

FDA Approves pembrolizumab (Keytruda) for patients with recurrent locally advanced or metastatic MCC

14 Jan 2019 3:02 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda; Merck) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software